PDCD1 and neoplasm: Beginning in 2021, pembrolizumab, an anti‐programmed death‐1 (PD‐1) inhibitor, has been recommended by the National Comprehensive Cancer Network guidelines for patients with OC exhibiting microsatellite instability‐high, mismatch repair‐deficient, or tumor mutational burden‐high tumors (≥10 mutations/megabase) who have no satisfactory alternative treatment options [4].